FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 338:653-662 March 5, 1998 Number 10 Next

Inactivating Mutations in the 25-Hydroxyvitamin D3 1-Hydroxylase Gene in Patients with Pseudovitamin D–Deficiency Rickets

Abstract PDF Editorial by Bouillon, R. Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited PubMed Citation

ABSTRACT

Background Pseudovitamin D–deficiency rickets is characterized by the early onset of rickets with hypocalcemia and is thought to be caused by a deficit in renal 25-hydroxyvitamin D₃ 1-hydroxylase, the key enzyme for the synthesis of 1,25-dihydroxyvitamin D₃.

Methods We cloned human 25-hydroxyvitamin D₃ 1-hydroxylase complementary DNA (cDNA) using a mouse 1-hydroxylase cDNA fragment as a probe. Its genomic structure was determined, and its chromosomal location was mapped by fluorescence in situ hybridization. We then identified mutations in the 1-hydroxylase gene in four unrelated patients with pseudovitamin D–deficiency rickets by DNA-sequence analysis. Both the normal and the mutant 1-hydroxylase proteins were expressed in COS-1 cells and were assayed for 1-hydroxylase activity.

Results The gene for 25-hydroxyvitamin D₃ 1-hydroxylase was mapped to chromosome 12q13.3, which had previously been reported to be the locus for pseudovitamin D–deficiency rickets by linkage analysis. Four different homozygous missense mutations were detected in this gene in the four patients with pseudovitamin D–deficiency rickets. The unaffected parents and one sibling tested were heterozygous for the mutations. Functional analysis of the mutant 1-hydroxylase protein revealed that all four mutations abolished 1-hydroxylase activity.

Conclusions Inactivating mutations in the 25-hydroxyvitamin D₃ 1-hydroxylase gene are a cause of pseudovitamin D–deficiency rickets.

Two other inherited types of rickets are known,⁴ and the mutated genes in patients with these diseases have been identified. The diseases are hypocalcemic vitamin D–resistant rickets, also known as type II vitamin D–dependent rickets, in which the gene for the vitamin D receptor is mutated,^5,6,7 and X-linked hypophosphatemic vitamin D–resistant rickets, in which the PEX gene (phosphate-regulating gene with homology to endopeptidases on the X chromosome) is mutated.⁸ In contrast, the molecular basis of pseudovitamin D–deficiency rickets has remained unclear, although the disease locus has been mapped to chromosome 12q14 by linkage analysis.⁹

Pseudovitamin D–deficiency rickets is distinguished from other types of hereditary rickets in that affected patients have low serum concentrations of 1,25-dihydroxyvitamin D and normal or high concentrations of 25-hydroxyvitamin D.^10,11 In these patients, physiologic doses of 1,25-dihydroxyvitamin D₃ but massive doses of vitamin D or 25-hydroxyvitamin D₃ are required to cure the rickets.¹² These findings suggest that the activity of renal 25-hydroxyvitamin D₃ 1-hydroxylase,^13,14 which converts 25-hydroxyvitamin D₃ to 1,25-dihydroxyvitamin D₃, is defective in patients with pseudovitamin D–deficiency rickets. Whether this defect is due to abnormalities in the 25-hydroxyvitamin D₃ 1-hydroxylase gene or to genetic abnormalities in other factors required for the full activity of this enzyme is unknown.^13,15 Since direct enzymatic measurement of 1-hydroxylase activity in these patients is difficult, the human 1-hydroxylase gene was cloned in the present study to investigate genetic mutations in patients with pseudovitamin D–deficiency rickets.

Using a novel vitamin D receptor–mediated expression cloning method,¹⁶ we recently cloned 1-hydroxylase complementary DNA (cDNA) from the kidneys of vitamin D receptor–deficient knockout mice in which the 1-hydroxylase gene was overexpressed.¹⁷ In the present study, we cloned human 1-hydroxylase cDNA, determined the structure of the gene and the chromosomal locus, and analyzed whether this gene is mutated in patients with pseudovitamin D–deficiency rickets.

Methods

Patients

We studied four unrelated Japanese patients with pseudovitamin D–deficiency rickets and four of their unaffected parents, one sibling, and one nephew. The diagnosis of pseudovitamin D–deficiency rickets in these patients was based on the early onset of hypocalcemia, radiologic findings characteristic of rickets, and the requirement of high doses of vitamin D and physiologic doses of 1-hydroxyvitamin D₃.^2,3 The clinical data on these patients are summarized in Table 1. The diagnosis was confirmed by low serum concentrations of 1,25-dihydroxyvitamin D determined when the patients were 10 to 20 years old, after the cessation of therapy with vitamin D₂ or 1-hydroxyvitamin D₃. The parents of Patient 1 were second cousins; those of Patient 2 were first cousins; those of Patient 3 were unrelated and came from the same remote area; those of Patient 4 were unrelated and came from different areas.

View this table: [in this window] [in a new window]   Table 1. Clinical and Biochemical Features in Four Patients with Pseudovitamin D–Deficiency Rickets.

 
The studies were approved by the appropriate institutional review committees, and all subjects gave informed consent.

Isolation of 1-Hydroxylase cDNA and Gene

A human kidney cDNA library was prepared from poly(A)+RNA purified from normal kidney tissue.¹⁹ A total of 1x10⁶ plaques were screened by hybridization with a mouse 1-hydroxylase cDNA N-terminal fragment (0.7 kb).¹⁶ Two positive plaques were subcloned and sequenced automatically in a Prism 377 DNA sequencer (Applied Biosystems, Foster City, Calif.), with AmpliTaq DNA polymerase FS (Perkin–Elmer, Norwalk, Conn.) and dye terminator.

The genomic sequence of human 1-hydroxylase was determined by sequencing the polymerase-chain-reaction (PCR) products amplified with three sets of primers specific to the exon and the untranslated region, with normal human leukocyte DNA as a template.

Fluorescence in Situ Hybridization

Three human genomic fragments covering all areas of the 1-hydroxylase gene were used as probes. Fluorescence in situ hybridization was carried out on more than 20 chromosomes in prometaphase.²⁰

PCR Amplification and Sequence Analysis of the 1-Hydroxylase Gene

Genomic DNA of all patients and family members was extracted from peripheral white cells. Exons of the 1-hydroxylase gene were amplified by PCR with specific primers derived from intronic sequences. Information about the sequence of the primers is available elsewhere (^*). AmpliTaq Gold (Perkin–Elmer) and its standard buffer were used in all reactions. All exons were amplified in a PCR thermocycler (Perkin–Elmer) by initial denaturation at 95°C for nine minutes, followed by 30 cycles at 95°C for one minute, 60°C for one minute, and 72°C for one minute. The corresponding PCR products were purified and sequenced directly in both directions.

Plasmid Construction

The wild-type human 1-hydroxylase cDNA was introduced into the expression vector pcDNA3 (Invitrogen, San Diego, Calif.), and the patients' mutations were introduced with a site-directed mutagenesis kit (Quick Change, Stratagene, La Jolla, Calif.). The expression plasmid for the ligand-binding domain of the vitamin D receptor (VDR) fused to the GAL4 DNA binding domain [GAL4-VDR(DEF)] was prepared as described elsewhere.²¹

Assay of 1-Hydroxylase Activity

1-Hydroxylase activity was assayed both by vitamin D receptor–mediated transactivation assay and by high-performance liquid chromatography.¹⁶ Briefly, for the vitamin D receptor–mediated transactivation assay, COS-1 cells were transiently transfected with 0.5 µg of GAL4-VDR(DEF), 1 µg of 17M2-G-CAT reporter plasmid,²² 0.2 µg each of the adrenodoxin and adrenodoxin reductase expression plasmids, 1 to 2 µg of either wild-type or mutant 1-hydroxylase expression plasmid, and 1 µg of -galactosidase expression plasmid pCH110 (Pharmacia Biotech, Uppsala, Sweden). Twelve hours after transfection, the ligands were added to the medium. After incubation for an additional 36 hours, cell extracts were prepared and used for chloramphenicol acetyltransferase assays.²³

For analysis by high-performance liquid chromatography, COS-1 cells were transfected with 0.5 µg each of adrenodoxin and adrenodoxin reductase expression plasmids and 3 µg of either wild-type or mutant 1-hydroxylase expression plasmid and were then incubated with tritiated 25-hydroxyvitamin D₃ for six hours. The incubation medium and cells were extracted and analyzed by normal-phase and reverse-phase high-performance liquid chromatography. The eluent fractions were collected, and the radioactivity was estimated by liquid-scintillation counting.^16,24,25 Authentic vitamin D derivatives were chromatographed, and the retention times were determined by ultraviolet absorption at 264 nm.

Results

Isolation of 25-Hydroxyvitamin D₃ 1-Hydroxylase cDNA and Gene

A 2.4-kb cDNA clone was isolated from a normal human kidney cDNA library by using the mouse 1-hydroxylase cDNA fragment as a probe. This cDNA contains a 1527-bp open reading frame predicted to encode a protein of 508 amino acids. The sequence of this cDNA was verified by determination of the genomic sequence.

The sequence of the coding region was 82 percent identical to that of mouse 1-hydroxylase at both the nucleotide and the amino acid levels.¹⁶ The deduced amino acid sequence of this cDNA has substantial homology with members of the mitochondrial P450 family,²⁶ particularly human vitamin D₃ 25-hydroxylase (CYP27, 40 percent),²⁷ 25-hydroxyvitamin D₃ 24-hydroxylase (CYP24, 32 percent),²⁸ P450scc (CYP11A, 33 percent),²⁹ and 11-hydroxylase (CYP11B1, 30 percent).³⁰

The structure of the human 1-hydroxylase gene was determined by PCR amplification of normal human leukocyte DNA, with use of exon-specific primers designed from the cDNA sequence, on the basis of the finding that the known members of the mitochondrial P450 family usually have short introns.³¹ The 1-hydroxylase gene consisted of nine exons spanning a region of approximately 4.8 kb.

Chromosomal Localization of the 1-Hydroxylase Gene

Fluorescence in situ hybridization revealed that the 1-hydroxylase gene was located on chromosome band 12q13.3 (Figure 1A and Figure 1B). Since the gene responsible for pseudovitamin D–deficiency rickets has been mapped to this locus,⁹ this finding suggested that pseudovitamin D–deficiency rickets is caused by a defect in the structural gene encoding 1-hydroxylase.

View larger version (35K): [in this window] [in a new window]   Figure 1. Chromosomal Localization of the 1-Hydroxylase Gene According to Fluorescence in Situ Hybridization. Panel A shows fluorescence in situ hybridization with three genomic 1-hydroxylase fragments covering the entire coding region as probes on chromosome preparations obtained from phytohemagglutinin-stimulated blood lymphocytes. The probes were labeled by nick translation with biotin-16–deoxyuridine triphosphate and detected with avidin–fluorescein (Boehringer Mannheim, Mannheim, Germany).20 Precise mapping of the gene was performed by using prophase-like chromosome spreads with higher-resolution banding. Hoechst (G-banding), propidium iodide (R-banding), and avidin–fluorescein images were merged and colored blue, red, and green, respectively. Fluorescence signals on the R-banded chromosomes are indicated by arrowheads. The inset is a larger image of chromosome 12 showing precise mapping of the gene. Panel B shows the idiogram of chromosome 12 indicating the localization of the 1-hydroxylase gene to 12q13.3. The vitamin D–receptor gene, the gene responsible for hypocalcemic vitamin D–resistant rickets, was previously mapped to 12q13–14, as indicated in the figure.32

 
Tissue Expression of the 1-Hydroxylase Gene

Using the human 1-hydroxylase cDNA clone as a probe, we examined its expression in various human tissues by Northern blot analysis. The 1-hydroxylase transcript (approximately 2.4 kb) was detected only in renal tissue (Figure 2).

View larger version (72K): [in this window] [in a new window]   Figure 2. Northern Blot Analysis of 1-Hydroxylase Gene Expression in Human Tissues. The expression of the 1-hydroxylase gene in various human tissues was analyzed by Northern blotting with 2 µg of poly(A)+RNA from each tissue (Clontech, Palo Alto, Calif.).33 The 0.7-kb cDNA fragment corresponding to the N-terminal region of human 1-hydroxylase was used as a probe, and the levels of expression of -actin and glutaraldehyde-3-phosphate dehydrogenase (G3PDH) served as internal controls.

 
Homozygous Mutations in the 1-Hydroxylase Gene in Patients with Pseudovitamin D–Deficiency Rickets

To determine whether the 1-hydroxylase gene was mutated in patients with pseudovitamin D–deficiency rickets, we analyzed genomic DNA from the four patients. Four different missense mutations in four different positions were detected in these patients (Figure 3A and Figure 3B). Patient 1 had a mutation in exon 2, Arg107His (CGC to CAC), and Patient 2 had a mutation in exon 2, Gly125Glu (GGA to GAA). Patient 3 had a mutation in exon 6, Arg335Pro (CGG to CCG), that eliminates a restriction site for HpaII. The presence of the mutation was further confirmed by digesting the PCR product of exon 6 with the enzyme (data not shown). Patient 4 had a mutation in exon 7, Pro382Ser (CCT to TCT). All these patients were homozygous for their mutations, and the parents and one sibling who were studied were all heterozygous carriers (Figure 3B). A nephew of Patient 4 was a normal homozygote.

View larger version (26K): [in this window] [in a new window]   Figure 3. Mutation Analysis of the 1-Hydroxylase Gene in Four Families with Pseudovitamin D–Deficiency Rickets. Panel A shows the positions of the missense mutations detected in the four patients with pseudovitamin D–deficiency rickets. The exons are numbered, and the positions of the primers used for PCR amplification of each exon are indicated by the arrows under the diagram. Panel B shows the mutations detected in each family. The affected probands are indicated by arrows. Homozygotes are indicated by solid circles (females) or squares (males), heterozygotes by half-solid circles or squares, and the one tested family member with no mutation by an open square. Those not studied are indicated by gray symbols. Relevant portions of the sequencing chromatograms obtained from a normal subject (left) and the affected proband (right) are shown, with the position of each nucleotide mutation (arrowhead) and amino acid substitution (asterisk) indicated.

 
Functional Analysis of Wild-Type and Mutant 1-Hydroxylase Proteins

The 1-hydroxylase activities of the wild-type and the mutant enzymes in the four patients were assessed by examining the ligand-induced transactivation function of the vitamin D receptor. The vitamin D receptor was activated only when the 25-hydroxyvitamin D₃ added to the culture medium was converted to an active ligand, possibly 1,25-dihydroxyvitamin D₃ (Figure 4A). The expression of wild-type 1-hydroxylase activated the reporter gene (Figure 4B, lanes 3 and 4), as in mouse 1-hydroxylase¹⁶ (lane 5). In contrast, none of the mutants (Figure 4B, lanes 8, 9, 10, and 11) increased the activity of the reporter gene. In vitro translation analysis indicated that the wild-type and the mutant plasmids were translated with similar efficiency at 55 kd in size (data not shown).

View larger version (39K): [in this window] [in a new window]   Figure 4. Functional Analysis of Wild-Type and Mutant 1-Hydroxylase Proteins. Panel A shows the schema of the assay system for 1-hydroxylase activity. COS-1 cells were transfected with GAL4-VDR(DEF), 17M2-G-CAT, adrenodoxin, and adrenodoxin reductase expression plasmids together with wild-type or mutant 1-hydroxylase expression plasmid in the presence of 25-hydroxyvitamin D3 (25(OH)D3). When the expressed 1-hydroxylase converts 25-hydroxyvitamin D3 into 1,25-dihydroxyvitamin D3 (1,25(OH)2D3), the activated GAL4-VDR(DEF) induces expression of chloramphenicol acetyltransferase (CAT) on the reporter gene (17M2-G-CAT) through the GAL4 upstream-activating sequence (GAL4-UAS), and 1-hydroxylase activity can be analyzed by chloramphenicol acetyltransferase assay. Panel B shows the 1-hydroxylase activity of wild-type and mutant 1-hydroxylase as determined by the assay shown in Panel A. Significant activation was not detected in the absence of 25-hydroxyvitamin D3 (lane 1) or 1-hydroxylase expression plasmid (lane 2); however, 1,25-dihydroxyvitamin D3 effectively induced chloramphenicol acetyltransferase activity (lanes 6 and 7). The expression of wild-type 1-hydroxylase induced chloramphenicol acetyltransferase activity in a dose-dependent way (lanes 3 and 4), as observed in mouse 1-hydroxylase (lane 5).16 In contrast, none of the mutants increased the activity of the reporter gene (lanes 8, 9, 10, and 11). The results of one representative chloramphenicol acetyltransferase assay and a graph corresponding to the mean (±SE) values for three independent experiments are shown. Panel C shows the conversion of 25-hydroxyvitamin D3 to 1,25-dihydroxyvitamin D3 by 1-hydroxylase as determined by high-performance liquid chromatography. The results of normal-phase high-performance liquid chromatography are shown on the left and those of reverse-phase high-performance liquid chromatography on the right. The upper panels show the retention times of authentic vitamin D derivatives (1-hydroxyvitamin D3 [1(OH)D3], 25-hydroxyvitamin D3, 24R,25-dihydroxyvitamin D3 [24R,25(OH)2D3], 1,25-dihydroxyvitamin D3, and 1,24R,25-trihydroxyvitamin D3 [1,24R,25(OH)3D3]) as determined by ultraviolet absorption at 264 nm. The lower panels show the production of 1,25-dihydroxyvitamin D3 as determined by high-performance liquid chromatography when COS-1 cells were transfected with wild-type 1-hydroxylase expression plasmid in the presence of tritiated 25-hydroxyvitamin D3. Note that the retention times of a converted metabolite matched those of authentic 1,25-dihydroxyvitamin D3 in both normal and reverse phases (arrows). Panel D shows the conversion of 25-hydroxyvitamin D3 to 1,25-dihydroxyvitamin D3 by the wild-type (lane 2) and mutant (lanes 3, 4, 5, and 6) 1-hydroxylase proteins. The activity of 1-hydroxylase was determined by high-performance liquid chromatography, as in Panel C. Note that all the mutants failed to convert 25-hydroxyvitamin D3 to 1,25-dihydroxyvitamin D3 (lanes 3, 4, 5, and 6). Values corresponding to the mean (±SE) for three independent experiments are shown.

 
The 1-hydroxylase activity of these mutants was assayed to determine the ability of the enzyme to catalyze the conversion of 25-hydroxyvitamin D₃ to 1,25-dihydroxyvitamin D₃. When tritiated 25-hydroxyvitamin D₃ was added to cells transfected with the wild-type 1-hydroxylase expression plasmid, a metabolite was detected (Figure 4C, lower panels) at a retention time identical to that of authentic 1,25-dihydroxyvitamin D₃ (Figure 4C, upper panels). However, none of the mutants converted 25-hydroxyvitamin D₃ into 1,25-dihydroxyvitamin D₃ (Figure 4D). These results indicate that the protein products of the four mutations found in the patients with pseudovitamin D–deficiency rickets had no 1-hydroxylase activity.

Discussion

The responsible genes and their mutations have been identified for two types of hereditary rickets besides pseudovitamin D–deficiency rickets.^5,6,7,8 We isolated a human cDNA encoding 25-hydroxyvitamin D₃ 1-hydroxylase and identified different homozygous missense mutations in this gene in four patients with pseudovitamin D–deficiency rickets. Each of the four mutations abolished 1-hydroxylase activity. The asymptomatic parents and sibling were heterozygous for the mutations, demonstrating the autosomal recessive inheritance of this disease. We conclude that pseudovitamin D–deficiency rickets is caused by inactivating mutations in the 1-hydroxylase gene.

We found no correlation between phenotype and genotype; all four mutations abolished 1-hydroxylase activity, and the clinical features in all four patients were similar. Clinical heterogeneity has been reported in pseudovitamin D–deficiency rickets,^2,34 and there may be other mutations that only partially reduce enzyme activity, as is the case with other P450 enzymes.^35,36 In a preliminary study of a patient who had pseudovitamin D–deficiency rickets with mild clinical features, we detected no mutations in the coding region (unpublished data), a fact that suggests that gene expression may be impaired by a mutation in the promoter region. Alternatively, there may be genetic heterogeneity in pseudovitamin D–deficiency rickets, and further analysis may reveal mutations in another gene. We found only homozygous mutations in the four patients, a result in agreement with the finding that in rare autosomal recessive diseases, homozygous mutations are frequent and compound heterozygotes are uncommon.³⁷

The mutated residue (Pro382Ser) in one of our patients was located in a conserved region among various P450 enzymes that is assumed to be required for substrate binding,^38,39 and another mutated residue (Gly125Glu) was located in the region corresponding to the proposed substrate-recognition site in the P450 family (CYP2).⁴⁰ These mutations probably abolish the activity of 1-hydroxylase by reducing its affinity for 25-hydroxyvitamin D₃. We do not know how the other two mutations abolish 1-hydroxylase activity, but because these four residues are highly conserved among several mitochondrial P450 enzymes, they are likely to be important for the enzymatic function of this protein.

With the data obtained in this study, we now know the molecular basis of all three major types of hereditary rickets. The phenotypes of pseudovitamin D–deficiency rickets and hypocalcemic vitamin D–resistant rickets are similar, except for alopecia in the latter and differences in serum concentrations of vitamin D metabolites.⁴ There are many endogenous vitamin D derivatives with biologic activity, ⁴¹ and therefore altered serum concentrations of vitamin D derivatives in these types of hereditary rickets may cause different changes.

Supported by a grant-in-aid from the Ministry of Education, Science, Sports, and Culture of Japan (to Dr. Kato).

We are indebted to Mr. Yoshikazu Masuhiro, Dr. Yasuo Yanagi, Dr. Seiji Fukumoto, Dr. Masato Kobori, Dr. Takehiko Yokomizo, Mr. Fumihiko Ichikawa, and Dr. Naoki Kubota for technical assistance; to Dr. Toshiyuki Yasuda and Dr. Ayako Tanae for providing data on patients; to Mr. Tatsuya Yoshizawa for helpful discussions; to Dr. Chifumi Kitanaka for valuable comments; to Dr. Yoshiyasu Yabusaki for the kind gift of adrenodoxin and adrenodoxin reductase cDNA plasmids; and to Chugai Pharmaceuticals for vitamin D–related compounds.

^* See NAPS document no. 05444 for one page of supplementary material. To order, contact NAPS c/o Microfiche Publications, 248 Hempstead Tpk., West Hempstead, NY 11552.

Source Information

From the Institute of Molecular and Cellular Biosciences, University of Tokyo, Tokyo (S. Kitanaka, K.T., A.M., T.S., J.Y., S. Kato); Core Research for Evolutional Science and Technology, Japan Science and Technology Corporation, Saitama (S. Kato); the Faculty of Bioresources, Mie University, Mie (K.O., M.N.); Tokyo Metropolitan Kiyose Children's Hospital, Tokyo (Y.H.); the Department of Pediatrics, Chiba University School of Medicine, Chiba (H.N.); and the Department of Endocrinology and Metabolism, National Children's Medical Research Center, Tokyo (T.T.) — all in Japan.

Address reprint requests to Dr. Kato at the Institute of Molecular and Cellular Biosciences, University of Tokyo, Yayoi, Bunkyo-ku, Tokyo 113-0032, Japan.

References

1. Prader A, Illig R, Heierli E. Eine besondere Form des primären vitamin-D-resistenten Rachitis mit Hypocalcämie und autosomal-dominantem Erbgang: die hereditäre Pseudo-Mangelrachitis. Helv Paediatr Acta 1961;16:452-468. 
2. Balsan S. Hereditary pseudo-deficiency rickets or vitamin D-dependency type I. In: Glorieux FH, ed. Rickets. New York: Raven Press, 1991:155-63.
3. Demay MB. Hereditary defects in vitamin D metabolism and vitamin D receptor defects. In: DeGroot LJ, Besser M, Burger HG, et al., eds. Endocrinology. 3rd ed. Vol. 2. Philadelphia: W.B. Saunders, 1995:1173-8.
4. Marx SJ. Vitamin D and other calciferols. In: Scriver CR, Beaudet AL, Sly WS, Valle D, eds. The metabolic and molecular bases of inherited disease. 7th ed. Vol. 2. New York: McGraw-Hill, 1995:3091-107.
5. Hughes MR, Malloy PJ, Kieback DG, et al. Point mutations in the human vitamin D receptor gene associated with hypocalcemic rickets. Science 1988;242:1702-1705. [Free Full Text]
6. Malloy PJ, Hochberg Z, Tiosano D, Pike JW, Hughes MR, Feldman D. The molecular basis of hereditary 1,25-dihydroxyvitamin D₃ resistant rickets in seven related families. J Clin Invest 1990;86:2071-2079.
7. Liberman UA, Marx SJ. Vitamin D resistance. In: Weintraub BD, ed. Molecular endocrinology: basic concepts and clinical correlations. New York: Raven Press, 1995:425-44.
8. The HYP Consortium. A gene (PEX) with homologies to endopeptidases is mutated in patients with X-linked hypophosphatemic rickets. Nat Genet 1995;11:130-136. [CrossRef][Medline]
9. Labuda M, Morgan K, Glorieux FH. Mapping autosomal recessive vitamin D dependency type I to chromosome 12q14 by linkage analysis. Am J Hum Genet 1990;47:28-36. [Medline]
10. Scriver CR, Reade TM, DeLuca HF, Hamstra AJ. Serum 1,25-dihydroxyvitamin D levels in normal subjects and in patients with hereditary rickets or bone disease. N Engl J Med 1978;299:976-979. [Abstract]
11. Delvin EE, Glorieux FH, Marie PJ, Pettifor JM. Vitamin D dependency: replacement therapy with calcitriol? J Pediatr 1981;99:26-34. [CrossRef][Medline]
12. Fraser D, Kooh SW, Kind HP, Holick MF, Tanaka Y, DeLuca HF. Pathogenesis of hereditary vitamin-D-dependent rickets: an inborn error of vitamin D metabolism involving defective conversion of 25-hydroxyvitamin D to 1,25-dihydroxyvitamin D. N Engl J Med 1973;289:817-822.
13. Henry HL. Vitamin D hydroxylases. J Cell Biochem 1992;49:4-9. [CrossRef][Medline]
14. Kawashima H, Torikai S, Kurokawa K. Localization of 25-hydroxyvitamin D₃ 1-hydroxylase and 24-hydroxylase along the rat nephron. Proc Natl Acad Sci U S A 1981;78:1199-1203. [Free Full Text]
15. Pedersen JI, Ghazarian JG, Orme-Johnson NR, DeLuca HF. Isolation of chick renal mitochondrial ferredoxin active in the 25-hydroxyvitamin D₃-1-hydroxylase system. J Biol Chem 1976;251:3933-3941. [Free Full Text]
16. Takeyama K, Kitanaka S, Sato T, Kobori M, Yanagisawa J, Kato S. 25-Hydroxyvitamin D₃ 1-hydroxylase and vitamin D synthesis. Science 1997;277:1827-1830. [Free Full Text]
17. Yoshizawa T, Handa Y, Uematsu Y, et al. Mice lacking the vitamin D receptor exhibit impaired bone formation, uterine hypoplasia and growth retardation after weaning. Nat Genet 1997;16:391-396. [CrossRef][Medline]
18. Sasaki T, Nakajima H, Suzuki S. Studies on the pathogenesis of hypophosphatemic vitamin D refractory rickets of the simple type or phosphatdiabetes. Endocrinol Jpn 1961;8:272-278. 
19. Kobori M, Nojima H. A simple treatment of DNA in a ligation mixture prior to electroporation improves transformation frequency. Nucleic Acids Res 1993;21:2782-2782. [Free Full Text]
20. Okumura K, Nogami M, Taguchi H, Hisamatsu H, Tanaka K. The genes for the -type HC3 (PMSA2) and -type HC5 (PMSB1) subunits of human proteasomes map to chromosomes 6q27 and 7p12-p13 by fluorescence in situ hybridization. Genomics 1995;27:377-379. [CrossRef][Medline]
21. Ebihara K, Masuhiro Y, Kitamoto T, et al. Intron retention generates a novel isoform of the murine vitamin D receptor that acts in a dominant negative way on the vitamin D signaling pathway. Mol Cell Biol 1996;16:3393-3400. [Abstract]
22. Kato S, Endoh H, Masuhiro Y, et al. Activation of the estrogen receptor through phosphorylation by mitogen-activated protein kinase. Science 1995;270:1491-1494. [Free Full Text]
23. Sasaki H, Harada H, Handa Y, et al. Transcriptional activity of a fluorinated vitamin D analog on VDR-RXR-mediated gene expression. Biochemistry 1995;34:370-377. [CrossRef][Medline]
24. Fujii H, Sato T, Kaneko S, et al. Metabolic inactivation of retinoic acid by a novel P450 differentially expressed in developing mouse embryos. EMBO J 1997;16:4163-4173. [CrossRef][Medline]
25. Mawer EB, Hayes ME, Heys SE, et al. Constitutive synthesis of 1,25-dihydroxyvitamin D₃ by a human small cell lung cancer cell line. J Clin Endocrinol Metab 1994;79:554-560. [Abstract]
26. Nelson DR, Kamataki T, Waxman DJ, et al. The P450 superfamily: update on new sequences, gene mapping, accession numbers, early trivial names of enzymes, and nomenclature. DNA Cell Biol 1993;12:1-51. [Medline]
27. Guo YD, Strugnell S, Back DW, Jones G. Transfected human liver cytochrome P-450 hydroxylates vitamin D analogs at different side-chain positions. Proc Natl Acad Sci U S A 1993;90:8668-8672. [Free Full Text]
28. Chen KS, Prahl JM, DeLuca HF. Isolation and expression of human 1,25-dihydroxyvitamin D₃ 24-hydroxylase cDNA. Proc Natl Acad SciU S A 1993;90:4543-7.
29. Chung BC, Matteson KJ, Voutilainen R, Mohandas TK, Miller WL. Human cholesterol side-chain cleavage enzyme, P450scc: cDNA cloning, assignment of the gene to chromosome 15, and expression in the placenta. Proc Natl Acad Sci U S A 1986;83:8962-8966. [Free Full Text]
30. Chua SC, Szabo P, Vitek A, Grzeschik KH, John M, White PC. Cloning of cDNA encoding steroid 11-hydroxylase (P450c11). Proc Natl Acad Sci U S A 1987;84:7193-7197. [Free Full Text]
31. Mornet E, Dupont J, Vitek A, White PC. Characterization of two genes encoding human steroid 11-hydroxylase (P-450₁₁). J Biol Chem 1989;264:20961-20967. [Free Full Text]
32. Labuda M, Fujiwara TM, Ross MV, et al. Two hereditary defects related to vitamin D metabolism map to the same region of human chromosome 12q13-14. J Bone Miner Res 1992;7:1447-1453. [Medline]
33. Takeyama K, Kojima R, Ohashi R, et al. Retinoic acid differentially up-regulates the gene expression of retinoic acid receptor and isoforms in embryo and adult rats. Biochem Biophys Res Commun 1996;222:395-400. [CrossRef][Medline]
34. Cowen J, Harris F. Late presentation of vitamin D-dependent rickets. Arch Dis Child 1980;55:964-966. [Abstract]
35. Yanase T, Simpson ER, Waterman MR. 17-Hydroxylase/17,20-lyase deficiency: from clinical investigation to molecular definition. Endocr Rev 1991;12:91-108. [Medline]
36. White PC, Tusie-Luna MT, New MI, Speiser PW. Mutations in steroid 21-hydroxylase (CYP21). Hum Mutat 1994;3:373-378. [CrossRef][Medline]
37. Kitanaka S, Katsumata N, Tanae A, et al. A new compound heterozygous mutation in the 11-hydroxysteroid dehydrogenase type 2 gene in a case of apparent mineralocorticoid excess. J Clin Endocrinol Metab 1997;82:4054-4058. [Free Full Text]
38. Nonaka Y, Matsukawa N, Morohashi K, et al. Molecular cloning and sequence analysis of cDNA encoding rat adrenal cytochrome P-450₁₁. FEBS Lett 1989;255:21-26. [CrossRef][Medline]
39. Kawajiri K, Gotoh O, Sogawa K, Tagashira Y, Muramatsu M, Fujii-Kuriyama Y. Coding nucleotide sequence of 3-methylcholanthrene-inducible cytochrome P-450d cDNA from rat liver. Proc Natl Acad Sci U S A 1984;81:1649-1653. [Free Full Text]
40. Gotoh O. Substrate recognition sites in cytochrome P450 family 2 (CYP2) proteins inferred from comparative analyses of amino acid and coding nucleotide sequences. J Biol Chem 1992;267:83-90. [Free Full Text]
41. Bouillon R, Okamura WH, Norman AW. Structure-function relationships in the vitamin D endocrine system. Endocr Rev 1995;16:200-257. [CrossRef][Medline]

Abstract PDF Editorial by Bouillon, R. Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited PubMed Citation

This article has been cited by other articles:

• Bailey, R., Cooper, J. D., Zeitels, L., Smyth, D. J., Yang, J. H.M., Walker, N. M., Hypponen, E., Dunger, D. B., Ramos-Lopez, E., Badenhoop, K., Nejentsev, S., Todd, J. A. (2007). Association of the Vitamin D Metabolism Gene CYP27B1 With Type 1 Diabetes. Diabetes 56: 2616-2621 [Abstract] [Full Text]  
• Kim, C. J., Kaplan, L. E., Perwad, F., Huang, N., Sharma, A., Choi, Y., Miller, W. L., Portale, A. A. (2007). Vitamin D 1{alpha}-Hydroxylase Gene Mutations in Patients with 1{alpha}-Hydroxylase Deficiency. J. Clin. Endocrinol. Metab. 92: 3177-3182 [Abstract] [Full Text]  
• Holick, M. F. (2007). Vitamin D Deficiency. NEJM 357: 266-281 [Full Text]  
• Vanhooke, J. L., Prahl, J. M., Kimmel-Jehan, C., Mendelsohn, M., Danielson, E. W., Healy, K. D., DeLuca, H. F. (2006). CYP27B1 null mice with LacZreporter gene display no 25-hydroxyvitamin D3-1{alpha}-hydroxylase promoter activity in the skin. Proc. Natl. Acad. Sci. USA 103: 75-80 [Abstract] [Full Text]  
• Xie, Z., Chang, S., Oda, Y., Bikle, D. D. (2006). Hairless Suppresses Vitamin D Receptor Transactivation in Human Keratinocytes. Endocrinology 147: 314-323 [Abstract] [Full Text]  
• Renkema, K. Y., Nijenhuis, T., van der Eerden, B. C.J., van der Kemp, A. W.C.M., Weinans, H., van Leeuwen, J. P.T.M., Bindels, R. J.M., Hoenderop, J. G.J. (2005). Hypervitaminosis D Mediates Compensatory Ca2+ Hyperabsorption in TRPV5 Knockout Mice. J. Am. Soc. Nephrol. 16: 3188-3195 [Abstract] [Full Text]  
• Yamamoto, K., Uchida, E., Urushino, N., Sakaki, T., Kagawa, N., Sawada, N., Kamakura, M., Kato, S., Inouye, K., Yamada, S. (2005). Identification of the Amino Acid Residue of CYP27B1 Responsible for Binding of 25-Hydroxyvitamin D3 Whose Mutation Causes Vitamin D-dependent Rickets Type 1. J. Biol. Chem. 280: 30511-30516 [Abstract] [Full Text]  
• Dusso, A. S., Brown, A. J., Slatopolsky, E. (2005). Vitamin D. Am. J. Physiol. Renal Physiol. 289: F8-F28 [Abstract] [Full Text]  
• Skorija, K., Cox, M., Sisk, J. M., Dowd, D. R., MacDonald, P. N., Thompson, C. C., Demay, M. B. (2005). Ligand-Independent Actions of the Vitamin D Receptor Maintain Hair Follicle Homeostasis. Mol. Endocrinol. 19: 855-862 [Abstract] [Full Text]  
• Levine, A. M., Tulpule, A., Espina, B., Sherrod, A., Boswell, W. D., Lieberman, R. D., Nathwani, B. N., Welles, L. (2004). Liposome-Encapsulated Doxorubicin in Combination With Standard Agents (cyclophosphamide, vincristine, prednisone) in Patients With Newly Diagnosed AIDS-Related Non-Hodgkin's Lymphoma: Results of Therapy and Correlates of Response. JCO 22: 2662-2670 [Abstract] [Full Text]  
• Yamasaki, T., Izumi, S., Ide, H., Ohyama, Y. (2004). Identification of a Novel Rat Microsomal Vitamin D3 25-Hydroxylase. J. Biol. Chem. 279: 22848-22856 [Abstract] [Full Text]  
• Kitanaka, S., Miki, Y., Hayashi, Y., Igarashi, T. (2004). Promoter-Specific Repression of Hepatocyte Nuclear Factor (HNF)-1{beta} and HNF-1{alpha} Transcriptional Activity by an HNF-1{beta} Missense Mutant Associated with Type 5 Maturity-Onset Diabetes of the Young with Hepatic and Biliary Manifestations. J. Clin. Endocrinol. Metab. 89: 1369-1378 [Abstract] [Full Text]  
• Zanello, L. P., Norman, A. W. (2004). Rapid modulation of osteoblast ion channel responses by 1{alpha},25(OH)2-vitamin D3 requires the presence of a functional vitamin D nuclear receptor. Proc. Natl. Acad. Sci. USA 101: 1589-1594 [Abstract] [Full Text]  
• Kip, S. N., Strehler, E. E. (2004). Vitamin D3 upregulates plasma membrane Ca2+-ATPase expression and potentiates apico-basal Ca2+ flux in MDCK cells. Am. J. Physiol. Renal Physiol. 286: F363-F369 [Abstract] [Full Text]  
• Yokomura, K., Suda, T., Sasaki, S., Inui, N., Chida, K., Nakamura, H. (2003). Increased Expression of the 25-Hydroxyvitamin D3-1{alpha}-Hydroxylase Gene in Alveolar Macrophages of Patients with Lung Cancer. J. Clin. Endocrinol. Metab. 88: 5704-5709 [Abstract] [Full Text]  
• van Abel, M., Hoenderop, J. G. J., van der Kemp, A. W. C. M., van Leeuwen, J. P. T. M., Bindels, R. J. M. (2003). Regulation of the epithelial Ca2+ channels in small intestine as studied by quantitative mRNA detection. Am. J. Physiol. Gastrointest. Liver Physiol. 285: G78-G85 [Abstract] [Full Text]  
• Singh, J, Moghal, N, Pearce, S H S, Cheetham, T (2003). The investigation of hypocalcaemia and rickets. Arch. Dis. Child. 88: 403-407 [Abstract] [Full Text]  
• Katsumata, N., Ohtake, M., Hojo, T., Ogawa, E., Hara, T., Sato, N., Tanaka, T. (2002). Compound Heterozygous Mutations in the Cholesterol Side-Chain Cleavage Enzyme Gene (CYP11A) Cause Congenital Adrenal Insufficiency in Humans. J. Clin. Endocrinol. Metab. 87: 3808-3813 [Abstract] [Full Text]  
• Carpenter, T. O. (2002). Variable Degrees of 1-{alpha} Hydroxylase Activity--Fine Tuning the Rachitic Rheostat. J. Clin. Endocrinol. Metab. 87: 2421-2423 [Full Text]  
• Wang, X., Zhang, M. Y. H., Miller, W. L., Portale, A. A. (2002). Novel Gene Mutations in Patients with 1{alpha}-Hydroxylase Deficiency That Confer Partial Enzyme Activity in Vitro. J. Clin. Endocrinol. Metab. 87: 2424-2430 [Abstract] [Full Text]  
• Yoshida, T., Yoshino, J., Hayashi, M., Saruta, T. (2002). Identification of a Renal Proximal Tubular Cell-Specific Enhancer in the Mouse 25-Hydroxyvitamin D 1{alpha}-Hydroxylase Gene. J. Am. Soc. Nephrol. 13: 1455-1463 [Abstract] [Full Text]  
• Kato, S. (2001). Editorial: Vitamin D 1{{alpha}}-Hydroxylase Knockout Mice as a Hereditary Rickets Animal Model. Endocrinology 142: 2734-2735 [Full Text]  
• Dardenne, O., Prud'homme, J., Arabian, A., Glorieux, F. H., St-Arnaud, R. (2001). Targeted Inactivation of the 25-Hydroxyvitamin D3-1{{alpha}}-Hydroxylase Gene (CYP27B1) Creates an Animal Model of Pseudovitamin D-Deficiency Rickets. Endocrinology 142: 3135-3141 [Abstract] [Full Text]  
• Yamagata, M., Kimoto, A., Michigami, T., Nakayama, M., Ozono, K. (2001). Hydroxylases Involved in Vitamin D Metabolism Are Differentially Expressed in Murine Embryonic Kidney: Application of Whole Mount in Situ Hybridization. Endocrinology 142: 3223-3230 [Abstract] [Full Text]  
• HOENDEROP, J. G. J., MULLER, D., VAN DER KEMP, A. W. C. M., HARTOG, A., SUZUKI, M., ISHIBASHI, K., IMAI, M., SWEEP, F., WILLEMS, P. H. G. M., OS, C. H. V., BINDELS, R. J. M. (2001). Calcitriol Controls the Epithelial Calcium Channel in Kidney. J. Am. Soc. Nephrol. 12: 1342-1349 [Abstract] [Full Text]  
• Panda, D. K., Miao, D., Tremblay, M. L., Sirois, J., Farookhi, R., Hendy, G. N., Goltzman, D. (2001). Targeted ablation of the 25-hydroxyvitamin D 1alpha -hydroxylase enzyme: Evidence for skeletal, reproductive, and immune dysfunction. Proc. Natl. Acad. Sci. USA 98: 7498-7503 [Abstract] [Full Text]  
• Tenenhouse, H. S., Martel, J., Gauthier, C., Zhang, M. Y. H., Portale, A. A. (2001). Renal Expression of the Sodium/Phosphate Cotransporter Gene, Npt2, Is Not Required for Regulation of Renal 1{{alpha}}-Hydroxylase by Phosphate. Endocrinology 142: 1124-1129 [Abstract] [Full Text]  
• Zehnder, D., Bland, R., Williams, M. C., McNinch, R. W., Howie, A. J., Stewart, P. M., Hewison, M. (2001). Extrarenal Expression of 25-Hydroxyvitamin D3-1{{alpha}}-Hydroxylase. J. Clin. Endocrinol. Metab. 86: 888-894 [Abstract] [Full Text]  
• Zargar, A. H., Mithal, A., Wani, A. I., Laway, B. A., Masoodi, S. R., Bashir, M. I., Ganie, M. A. (2000). Pseudovitamin D deficiency rickets---a report from the Indian subcontinent. Postgrad. Med. J. 76: 369-372 [Abstract] [Full Text]  
• YOSHIDA, N., YOSHIDA, T., NAKAMURA, A., MONKAWA, T., HAYASHI, M., SARUTA, T. (1999). Calcitonin Induces 25-Hydroxyvitamin D3 1{alpha}-Hydroxylase mRNA Expression via Protein Kinase C Pathway in LLC-PK1 Cells. J. Am. Soc. Nephrol. 10: 2474-2479 [Abstract] [Full Text]  
• Kitanaka, S., Murayama, A., Sakaki, T., Inouye, K., Seino, Y., Fukumoto, S., Shima, M., Yukizane, S., Takayanagi, M., Niimi, H., Takeyama, K.-i., Kato, S. (1999). No Enzyme Activity of 25-Hydroxyvitamin D3 1{alpha}-Hydroxylase Gene Product in Pseudovitamin D Deficiency Rickets, Including That with Mild Clinical Manifestation. J. Clin. Endocrinol. Metab. 84: 4111-4117 [Abstract] [Full Text]  
• Brown, A. J., Dusso, A., Slatopolsky, E. (1999). Vitamin D. Am. J. Physiol. Renal Physiol. 277: F157-F175 [Abstract] [Full Text]  
• Jones, G., Ramshaw, H., Zhang, A., Cook, R., Byford, V., White, J., Petkovich, M. (1999). Expression and Activity of Vitamin D-Metabolizing Cytochrome P450s (CYP1{alpha} and CYP24) in Human Nonsmall Cell Lung Carcinomas. Endocrinology 140: 3303-3310 [Abstract] [Full Text]  
• Kong, X. F., Zhu, X. H., Pei, Y. L., Jackson, D. M., Holick, M. F. (1999). Molecular cloning, characterization, and promoter analysis of the human 25-hydroxyvitamin D3-1alpha -hydroxylase gene. Proc. Natl. Acad. Sci. USA 96: 6988-6993 [Abstract] [Full Text]  
• John, E. M., Schwartz, G. G., Dreon, D. M., Koo, J. (1999). Vitamin D and Breast Cancer Risk: The NHANES I Epidemiologic Follow-up Study, 1971-1975 to 1992. Cancer Epidemiol. Biomarkers Prev. 8: 399-406 [Abstract] [Full Text]  
• Bland, R., Walker, E. A., Hughes, S. V., Stewart, P. M., Hewison, M. (1999). Constitutive Expression of 25-Hydroxyvitamin D3-1{alpha}-Hydroxylase in a Transformed Human Proximal Tubule Cell Line: Evidence for Direct Regulation of Vitamin D Metabolism by Calcium. Endocrinology 140: 2027-2034 [Abstract] [Full Text]  
• Murayama, A., Takeyama, K.-i., Kitanaka, S., Kodera, Y., Kawaguchi, Y., Hosoya, T., Kato, S. (1999). Positive and Negative Regulations of the Renal 25-Hydroxyvitamin D3 1{alpha}-Hydroxylase Gene by Parathyroid Hormone, Calcitonin, and 1{alpha},25(OH)2D3 in Intact Animals. Endocrinology 140: 2224-2231 [Abstract] [Full Text]  
• YOSHIDA, T., YOSHIDA, N., NAKAMURA, A., MONKAWA, T., HAYASHI, M., SARUTA, T. (1999). Cloning of Porcine 25-Hydroxyvitamin D3 1{alpha}-Hydroxylase and Its Regulation by cAMP in LLC-PK1 Cells. J. Am. Soc. Nephrol. 10: 963-970 [Abstract] [Full Text]  
• Malloy, P. J., Pike, J. W., Feldman, D. (1999). The Vitamin D Receptor and the Syndrome of Hereditary 1,25-Dihydroxyvitamin D-Resistant Rickets. Endocr. Rev. 20: 156-188 [Abstract] [Full Text]  
• Hoenderop, J. G. J., van der Kemp, A. W. C. M., Hartog, A., van de Graaf, S. F. J., van Os, C. H., Willems, P. H. G. M., Bindels, R. J. M. (1999). Molecular Identification of the Apical Ca2+ Channel in 1,25-Dihydroxyvitamin D3-responsive Epithelia. J. Biol. Chem. 274: 8375-8378 [Abstract] [Full Text]  
• Chesney, R. W. (1998). A New Form of Rickets During Infancy: Phosphate Depletion-Induced Osteopenia Due to Antacid Ingestion. Arch Pediatr Adolesc Med 152: 1168-1169 [Full Text]  
• Bouillon, R. (1998). The Many Faces of Rickets. NEJM 338: 681-682 [Full Text]  
• Chen, H., Hu, B., Allegretto, E. A., Adams, J. S. (2000). The Vitamin D Response Element-binding Protein. A NOVEL DOMINANT-NEGATIVE REGULATOR OF VITAMIN D-DIRECTED TRANSACTIVATION. J. Biol. Chem. 275: 35557-35564 [Abstract] [Full Text]